All In Biotech

Drug Trial Radar · NCT07911514

A Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234

A Phase I, Single-Dose, Randomised, Parallel-Group, Open-Label Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 in Participants Living With Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 9, 2026

Primary completion

May 4, 2027

Study completion May 4, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Quotient Sciences
First posted
Nov 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234. This study will take place at one site in Nottingham, United Kingdom, and will randomize 60 healthy men and women aged 18-55 years living with overweight/obesity.

Conditions

  • Healthy Participants

Interventions

  • AZD9550 solution for injectionDrug

    AZD9550 solution for injection will be administered as a single SC injection

  • AZD6234 solution for injectionDrug

    AZD6234 solution for injection will be administered as a single SC injection

  • Formulation 1 solution for injectionDrug

    Formulation 1 solution for injection will be administered as a single SC injection

  • Formulation 2 solution for injectionDrug

    Formulation 2 solution for injection will be administered as a single SC injection

  • Formulation 3 solution for injectionDrug

    Formulation 3 solution for injection will be administered as a single SC injection

  • Formulation 4 solution for injectionDrug

    Formulation 4 solution for injection will be administered as a single SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax)Time frame: Plasma sample collection from pre dose to Day 22
  2. Area under the curve from time 0 to the time of last quantifiable concentration (AUClast)Time frame: Plasma sample collection from pre dose to Day 22
  3. Area under the curve from time 0 extrapolated to infinity (AUCinf)Time frame: Plasma sample collection from pre dose to Day 22

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Ruddington, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.